California Institute for Biomedical Research (Calibr)
The California Institute for Biomedical Research (Calibr) is an independent not-for-profit institute established in 2012 with the goal of accelerating the translation of basic research to new medicines that address unmet medical needs. Collaborations with researchers across the world expedite the translation of basic biomedical findings to new candidate therapeutics, while enabling commercial partnerships are formed to bring these new medicines to the public. Value created from these activities is reinvested in preclinical and clinical research at the institute to create a self-sustaining, ‘evergreen’ model for not-for-profit biomedical research.
Calibr’s research interests span a broad range of human diseases, including cancer, autoimmunity and inflammatory diseases, metabolic and cardiovascular diseases, infectious and neglected diseases, as well as age-related and degenerative diseases. Calibr’s research space includes a newly renovated 50,000 square foot facility in La Jolla, CA, which houses over 130 interdisciplinary scientists and staff with state-of-the-art instrumentation. This infrastructure, combined with Calibr’s drug discovery expertise, enables projects rooted in novel therapeutic mechanisms to progress from the laboratory bench through preclinical development and ultimately to the clinic either independently or through commercial partnerships. Peter G. Schultz serves as the Institute Director and the Institute is governed by an independent Board of Directors. The Institute also receives strategic scientific input from an ad hoc Scientific Advisory Board chaired by Christopher T. Walsh.
Calibr receives financial support from foundations, federal and state government, and pharmaceutical industry partners. The Institute has received over $250 million in committed programmatic or unrestricted research funding since its inception in 2012. Major sources of funding include the Bill & Melinda Gates Foundation, the Wellcome Trust, JDRF, GATB, Cure SMA, CIRM and other state and federal agencies, which have enabled Calibr to accelerate efforts to discover innovative new medicines. In addition, Calibr has received funding from Merck, BMS and Pfizer for both preclinical and clinical development stage programs.
Calibr augments a robust internal research portfolio through collaboration with leaders in the academic research community. As a not-for-profit research institute, Calibr leverages its ability to readily form partnerships with academic and other non-profit institutions. Calibr currently has over 20 collaborative research projects and is actively seeking out new opportunities of high mutual interest. Calibr is currently pursuing a close alliance with The Scripps Research Institute and local clinical centers in order to create a highly effective “bench-to-bedside” model that accelerates the time and decreases the cost of developing new medicines for the public benefit.
Training young scientists in translational research is critical to the ongoing discovery of innovative new medicines. Calibr’s postdoctoral fellow program accepts the best and brightest candidates from multiple disciplines to train in all aspects of translational research, while developing their skills in grant writing and encouraging publication in high impact journals. The program equips fellows to tackle major challenges in modern medicine as they move forward in their own independent careers.
Calibr maintains a commitment to addressing unmet needs across all of human health, and has created a diverse project portfolio that impacts a number of therapeutic areas. Moreover, we have already managed to build a broad pipeline extending from early stage discovery through clinic-ready programs, the outputs of which are candidate medicines ranging from small molecules and peptides to biotherapeutics and cell-based therapies.See more